STK36抗体;STK36 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12249(STK36 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12249(STK36 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The STK36 antibody is a research tool targeting serine/threonine kinase 36 (STK36), also known as fused kinase (FU), a critical component of the Hedgehog (Hh) signaling pathway. STK36 regulates Gli transcription factors, which mediate Hh-dependent gene expression essential for embryonic development, tissue homeostasis, and cancer progression. Structurally, STK36 contains a kinase domain and a C-terminal region that interacts with other pathway components, such as SUFU and KIF7. Dysregulation of STK36 is linked to developmental disorders, ciliopathies, and malignancies like medulloblastoma and basal cell carcinoma.

Antibodies against STK36 are widely used to study its expression, localization, and functional roles in biological systems. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping researchers map its tissue distribution and subcellular behavior—particularly in primary cilia, where Hh signaling is orchestrated. Some antibodies also facilitate investigations into post-translational modifications or protein-protein interactions critical for pathway activation. As aberrant Hh signaling drives numerous diseases, STK36 antibodies serve as vital reagents for exploring molecular mechanisms and evaluating therapeutic strategies targeting this pathway. Their specificity and validation remain essential for ensuring reproducibility in studies linking STK36 dysregulation to pathophysiology.